Pfizer Inc.

NYSE:PFE

Drug Manufacturers - General

Healthcare
$28.06 -2.72%

-$0.71 today

Market cap
$159.94B
Beta
0.29
P/E (TTM)
19.2
EPS (TTM)
$1.32
Dividend yield
6.82%
52W Low $23.11High $28.75

Volume 37.37M

Average 36.66M

PFE Interest Expense

Cost of servicing the company's debt during the period.

Pfizer Inc.NYSE: PFE

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense growth accelerates

Q2 FY2026 interest expense of $667M rose 2.0% year over year, ahead of the -4.7% change in trailing-twelve-month interest expense. Sequentially, it fell 0.1% from the prior quarter. Over 3 fiscal years it compounded at +29.2% a year.

Context

  • Interest expense amounted to 4.3% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2.0% holds above the trailing-twelve-month pace of -4.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$667M-0.1% QoQ
Last fiscal yearDec 2025
$2.67B-13.6% YoY
LTMJun 2026
$2.7B-4.7% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.0%——
1 year-13.6%——
3-year CAGR+29.2%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
2.67B USD
Year-over-year change
-13.6%
4-year CAGR
+19.9%

Interest Expense vs competitors

How PFE compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -4.7% is the 8th highest of 11, against a peer median of -0.2%.
  • Interest expense amounts to 4.2% of revenue for PFE, versus a peer median of 2.3%.
PFE Competitors
Interest Expense for PFE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABBVAbbVie Inc.LTM Sep 2026$2.88B USD-0.1%+9.1%4.4%
PFEPfizer Inc.LTM Jun 2026$2.7B USD-4.7%+29.2%4.2%
AZNAstraZeneca PLCLTM Sep 2026$1.77B USD+7.2%+8.4%2.8%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$1.73B USD-12.6%+15.4%3.5%
NVSNovartis AGLTM Jun 2026$1.39B USD+26.0%+12.5%2.5%
MRKMerck & Co., Inc.LTM Jun 2026$1.26B USD-1.0%+12.2%1.9%
GILDGilead Sciences, Inc.LTM Jun 2026$998M USD-0.3%+3.1%3.3%
LLYEli Lilly and CompanyLTM Jun 2026$979.6M USD+7.6%+33.9%1.2%
JNJJohnson & JohnsonLTM Sep 2026$798M USD-10.7%+52.1%0.8%
GSKGSK plcLTM Jun 2026£690M GBP+6.8%-7.1%2.1%
SNYSanofiLTM Jun 2026€591.41M EUR-39.7%+17.6%1.2%
Peer median (excluding PFE) —-0.2%+12.3%2.3%

Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue81.29B101.18B59.55B63.63B62.58B
Cost of Revenue30.82B34.34B24.95B17.85B16.07B
Gross Profit50.47B66.83B34.6B45.78B46.51B
Gross Margin62.1%66.1%58.1%71.9%74.3%
Research & Development13.83B11.43B10.68B10.82B10.44B
Selling, General & Admin12.7B13.68B14.77B14.73B13.79B
Operating Expenses30.23B28.71B30.18B30.84B29.11B
Depreciation & Amortization5.19B5.06B6.29B7.01B6.59B
EBITDA30.79B41.03B9.56B18.13B16.78B
EBITDA Margin37.9%40.6%16.0%28.5%26.8%
Operating Income20.24B38.12B4.42B14.94B17.41B
Operating Margin24.9%37.7%7.4%23.5%27.8%
Interest Income36M251M1.62B545M603M
Interest Expense1.29B1.24B2.21B3.09B2.67B
Other Income / Expenses4.08B(3.39B)(3.36B)(6.92B)(9.89B)
Income Before Tax24.31B34.73B1.06B8.02B7.52B
Pre-Tax Margin29.9%34.3%1.8%12.6%12.0%
Income Tax Expense1.85B3.33B(1.12B)(28M)(266M)
Net Income21.98B31.37B2.12B8.03B7.77B
Net Margin27.0%31.0%3.6%12.6%12.4%
EPS (Basic)3.955.590.381.421.36
EPS (Diluted)3.885.470.371.411.36
Weighted Avg Shares5.6B5.61B5.64B5.66B5.68B
Weighted Avg Shares (Diluted)5.71B5.73B5.71B5.7B5.69B

Pfizer Inc.

NYSE:PFE

Intrinsic Alpha fair value

Locked

Current Price

$28.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.